Cargando…
Clinical Manifestations of Human Exposure to Fungi
Biological particles, along with inorganic gaseous and particulate pollutants, constitute an ever-present component of the atmosphere and surfaces. Among these particles are fungal species colonizing almost all ecosystems, including the human body. Although inoffensive to most people, fungi can be r...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052331/ https://www.ncbi.nlm.nih.gov/pubmed/36983549 http://dx.doi.org/10.3390/jof9030381 |
_version_ | 1785015135844171776 |
---|---|
author | Oliveira, Manuela Oliveira, Diana Lisboa, Carmen Boechat, José Laerte Delgado, Luís |
author_facet | Oliveira, Manuela Oliveira, Diana Lisboa, Carmen Boechat, José Laerte Delgado, Luís |
author_sort | Oliveira, Manuela |
collection | PubMed |
description | Biological particles, along with inorganic gaseous and particulate pollutants, constitute an ever-present component of the atmosphere and surfaces. Among these particles are fungal species colonizing almost all ecosystems, including the human body. Although inoffensive to most people, fungi can be responsible for several health problems, such as allergic fungal diseases and fungal infections. Worldwide fungal disease incidence is increasing, with new emerging fungal diseases appearing yearly. Reasons for this increase are the expansion of life expectancy, the number of immunocompromised patients (immunosuppressive treatments for transplantation, autoimmune diseases, and immunodeficiency diseases), the number of uncontrolled underlying conditions (e.g., diabetes mellitus), and the misusage of medication (e.g., corticosteroids and broad-spectrum antibiotics). Managing fungal diseases is challenging; only four classes of antifungal drugs are available, resistance to these drugs is increasing, and no vaccines have been approved. The present work reviews the implications of fungal particles in human health from allergic diseases (i.e., allergic bronchopulmonary aspergillosis, severe asthma with fungal sensitization, thunderstorm asthma, allergic fungal rhinosinusitis, and occupational lung diseases) to infections (i.e., superficial, subcutaneous, and systemic infections). Topics such as the etiological agent, risk factors, clinical manifestations, diagnosis, and treatment will be revised to improve the knowledge of this growing health concern. |
format | Online Article Text |
id | pubmed-10052331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100523312023-03-30 Clinical Manifestations of Human Exposure to Fungi Oliveira, Manuela Oliveira, Diana Lisboa, Carmen Boechat, José Laerte Delgado, Luís J Fungi (Basel) Review Biological particles, along with inorganic gaseous and particulate pollutants, constitute an ever-present component of the atmosphere and surfaces. Among these particles are fungal species colonizing almost all ecosystems, including the human body. Although inoffensive to most people, fungi can be responsible for several health problems, such as allergic fungal diseases and fungal infections. Worldwide fungal disease incidence is increasing, with new emerging fungal diseases appearing yearly. Reasons for this increase are the expansion of life expectancy, the number of immunocompromised patients (immunosuppressive treatments for transplantation, autoimmune diseases, and immunodeficiency diseases), the number of uncontrolled underlying conditions (e.g., diabetes mellitus), and the misusage of medication (e.g., corticosteroids and broad-spectrum antibiotics). Managing fungal diseases is challenging; only four classes of antifungal drugs are available, resistance to these drugs is increasing, and no vaccines have been approved. The present work reviews the implications of fungal particles in human health from allergic diseases (i.e., allergic bronchopulmonary aspergillosis, severe asthma with fungal sensitization, thunderstorm asthma, allergic fungal rhinosinusitis, and occupational lung diseases) to infections (i.e., superficial, subcutaneous, and systemic infections). Topics such as the etiological agent, risk factors, clinical manifestations, diagnosis, and treatment will be revised to improve the knowledge of this growing health concern. MDPI 2023-03-21 /pmc/articles/PMC10052331/ /pubmed/36983549 http://dx.doi.org/10.3390/jof9030381 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Oliveira, Manuela Oliveira, Diana Lisboa, Carmen Boechat, José Laerte Delgado, Luís Clinical Manifestations of Human Exposure to Fungi |
title | Clinical Manifestations of Human Exposure to Fungi |
title_full | Clinical Manifestations of Human Exposure to Fungi |
title_fullStr | Clinical Manifestations of Human Exposure to Fungi |
title_full_unstemmed | Clinical Manifestations of Human Exposure to Fungi |
title_short | Clinical Manifestations of Human Exposure to Fungi |
title_sort | clinical manifestations of human exposure to fungi |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052331/ https://www.ncbi.nlm.nih.gov/pubmed/36983549 http://dx.doi.org/10.3390/jof9030381 |
work_keys_str_mv | AT oliveiramanuela clinicalmanifestationsofhumanexposuretofungi AT oliveiradiana clinicalmanifestationsofhumanexposuretofungi AT lisboacarmen clinicalmanifestationsofhumanexposuretofungi AT boechatjoselaerte clinicalmanifestationsofhumanexposuretofungi AT delgadoluis clinicalmanifestationsofhumanexposuretofungi |